This medicinal product does not have UK marketing authorisation but has been given authorisation only for temporary supply.
2/11
The official Phase III safety trials will not be completed until 2023.
3/11
Will you be truly “protected” from COVID-19?
4/11
The complicated multistage dilution and thawing process of the vaccine vials opens the major possibility of human error.
5/11
The safety and efficacy of COVID-19 mRNA Vaccine BNT162b2 in children under 16 years of age have not yet been established.
6/11
No data are available on the use of COVID-19 mRNA Vaccine BNT162b2 in persons that have previously received a full or partial vaccine series with another COVID-19 vaccine.
7/11
No interaction studies have been performed and there are no, or a limited amount of, data from the use of COVID-19 mRNA Vaccine BNT162b2.
8/11
It is unknown whether COVID-19 mRNA Vaccine BNT162b2 is excreted in human milk and It is unknown whether COVID-19 mRNA Vaccine BNT162b2 has an impact on fertility.
9/11
Non-clinical data reveal no special hazard for humans based on a conventional study of repeat dose toxicity but animal studies into potential toxicity to reproduction and development have not been completed.
10/11
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.
11/11.
ENDS
You can follow @VernersViews.
Tip: mention @twtextapp on a Twitter thread with the keyword “unroll” to get a link to it.

Latest Threads Unrolled:

By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.